White horse trotting in a paddock at sunset

PROMOVET® JOINT

The freedom of movement

Every joint tells the horse's story:
work, performance, recovery, experience.

PROMOVET® JOINT is based on an innovative, patented formulation technology, developed to support the horse's joint wellbeing over time, respecting joint physiology and preserving the harmony of movement.
Because the real goal is not only to deliver an immediate benefit, but to support movement consistently over time.
Scientific research underpins every choice: from ingredient selection to formulation development, through to solutions that combine efficacy, safety and formulation elegance.

THE PRODUCT

Beyond traditional viscosupplementation

PROMOVET® JOINT is an intra-articular veterinary device based on an innovative cross-linked carboxymethylcellulose (CMC) and croscarmellose hydrogel, the result of patented Italian technology.
Italian patent no. 102020000020224

The formulation is designed to interact with the joint environment by creating a protective mechanical barrier and by exploiting the viscoelastic and thixotropic properties of the hydrogel.
The result is joint support that evolves over time, physiologically supporting the recovery of joint function.

REQUEST INFORMATION
Hands palpating a horse's limb beside the PROMOVET JOINT pack and syringe

PRODUCT INFORMATION

PROMOVET® JOINT is a sterile, isotonic, cross-linked gel for intra-articular administration, developed for joint viscosupplementation in cases of osteoarthritis, reduced joint mobility and cartilage degeneration of various aetiologies.
The formulation acts as a synovial fluid substitute, helping to restore the rheological properties of the joint environment, promoting joint function and supporting its natural biomechanical balance. It is particularly indicated in older horses and in animals subject to high or prolonged joint loads.
PROMOVET® JOINT is a single-use device that acts exclusively at the injection site. It has no systemic action and is intended solely for intra-articular administration.
The product does not require a veterinary prescription; however, sale is restricted to veterinary surgeons and administration must be carried out by a veterinary surgeon only.

Intended use: for non-food-producing horses only (not intended for the production of food for human consumption).

COMPOSITION:

Sodium carboxymethylcellulose, croscarmellose sodium, sodium chloride, sodium phosphate monobasic dihydrate, sodium phosphate dibasic dodecahydrate, water for injection, sodium hydroxide solution 30%.

FORMULATION TECHNOLOGY:

PROMOVET JOINT 3 ml pre-filled syringe

CROSCARMELLOSE

A cross-linked derivative of plant-based cellulose, characterised by a high capacity to absorb water and to expand the three-dimensional structure of the hydrogel.
In combination with carboxymethylcellulose, it gives the formulation the rheological properties needed to sustain joint viscosupplementation, promoting the persistence of the gel within the joint and helping to maintain its viscoelastic properties.

CARBOXYMETHYLCELLULOSE (CMC)

A plant-based polymer derived from cellulose, widely used in the biomedical field for its viscoelastic properties and high biocompatibility. Its safety has also been recognised for use in feed for all animal species (EFSA, 2020).
In the PROMOVET® JOINT formulation, carboxymethylcellulose in its sodium salt form helps to create a viscous hydrogel with a lubricating action, promoting viscosupplementation and mechanical support of the joint environment.

SAFETY

The technology based on carboxymethylcellulose (CMC) and croscarmellose has undergone specific preclinical assessments that confirmed its favourable biocompatibility profile.
The tests carried out showed:

  • no cytotoxicity, confirming the compatibility of the formulation with biological tissues;
  • no systemic toxicity, demonstrating that the device acts exclusively at joint level;
  • intra-articular persistence of the device, documented by ultrasound examination up to 52 weeks after administration, supporting the persistence of the formulation at the implant site.

This evidence confirms the safety profile of PROMOVET® JOINT and supports a technology developed to act mechanically and locally, in respect of joint physiology.

EFFICACY

PROMOVET® JOINT was evaluated in a prospective randomised clinical study in horses with fetlock osteoarthritis, carried out by the University of Bologna(*).
The results showed a progressive clinical improvement in joint function and lameness, maintained up to 90 days after treatment. Unlike conventional treatments, the clinical response was more gradual but longer lasting.
These results confirm the formulation approach of PROMOVET® JOINT: supporting the natural balance of the joint through purpose-designed viscosupplementation that accompanies the physiological recovery of the joint.

Clinical success over time

  • PROMOVET® JOINT
  • HA + Cortisone
Success = reduction of ≥1 AAEP lameness grade without additional treatment. T90 HA + Cortisone: 1/14 horses (=7.1%).
Clinical success over time (%)
T15T30T90
PROMOVET® JOINT20%75%75%
HA + Cortisone90%75%7,1%

(*) Rinnovati, R., Spadari, A., Malpighi, A., Meistro, F., Ralletti, M.V., Marcucci, E., et al. (2025). Evaluation of an intra-articular carboxymethylcellulose crosslinked hydrogel in horses with osteoarthritis. JOURNAL OF EQUINE VETERINARY SCIENCE, 150, 1-4 [10.1016/j.jevs.2025.105611]